Identifying Optimal Immunochemotherapy for Patients With Mantle Cell Lymphoma
Few population-based studies have compared treatment approaches in the setting of mantle cell lymphoma.
Diagnosis & Disease Information
Addition of Venetoclax to Azacitidine Associated With Clinically Significant OS Benefit in AML
The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.
Addition of Isatuximab to Kd Deepens Responses and Extends PFS in R/R Multiple Myeloma
The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.
Ropeginterferon Appears to Improve Polycythemia Vera Symptoms
The purpose of this study was to determine if a cytoreductive agent could provide additional efficacy to treat blood hyperviscosity.
FLT3-ITD With an Insertion Site in the Beta1-Sheet Prognostic for Poor Outcomes in AML
Among adult patients with newly diagnosed AML, the presence of an FLT3-ITD mutation with an insertion site in the beta1-sheet was associated shorter survival.
Ixazomib Found Effective as a Maintenance Therapy in Patients With Newly Diagnosed MM Who Are Ineligible for Transplant
Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.
Characteristics of Ruxolitinib Discontinuation Syndrome in Myelofibrosis
Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.
Real World Evidence Shows OS Improvements in Older Patients With AML From 2000 to 2016
A population-based study included nearly 4000 patients diagnosed with AML from 2000 to 2016 in Denmark.
Overall Survival Improved After Fewer Chemotherapy Cycles in Advanced Hodgkin Lymphoma: Long-Term Follow-Up of GHSG HD18 Trial
Researchers presented findings of a significantly higher 5-year OS rate in patients who received 4 cycles of eBEACOPP compared with patients who received 6/8 cycles.
Study Provides Support for TKI Discontinuation in Some Patients With CML
This population-based study of patients with chronic phase CML evaluated the BCR/ABL1 TKI discontinuation rates for patients treated on and off a clinical trial.
- Loading...
Loading...
Next post in EHA25 Virtual Congress
Loading... 
Loading...